Navigation Links
NeuroDerm Successfully Completes Enrollment and Dosing in a Phase 1 Clinical Study of ND0611 Dermal Patch for Parkinson's Disease
Date:6/1/2010

NESS ZIONA, Israel, June 1, 2010 /PRNewswire/ -- NeuroDerm, Ltd. announced today the successful enrollment and dosing in its Phase I clinical trial of ND0611. ND0611, a proprietary drug formula administered via a dermal patch, is designed to maintain continuous therapeutic levodopa concentrations for improving the treatment of Parkinson's disease.

ND0611 increases levodopa bioavailability and extends its effects by administering a novel pharmaceutical. Previous animal studies found that ND0611 modified levodopa pharmacokinetics by (i) increasing levodopa plasma half-life and area-under-the-curve (AUC), (ii) maintaining levodopa plasma concentrations in a typical therapeutic range, and (iii) extending dopaminergic stimulation in the brain. ND0611's mode of action involves an under-exploited levodopa metabolic pathway and has the potential for markedly improving clinical benefits from levodopa (the most effective drug for Parkinson's disease).

This Phase 1 study was conducted in healthy volunteers with the purpose of measuring the safety and tolerability of ND0611 at different doses. Further analysis will be completed to determine the pharmacokinetic profile of levodopa in plasma. The company expects to present the results of this phase 1 study in the second half of 2010.

"The completion of this first step in the clinical development of ND0611 marks an important milestone in the path to develop a new therapeutic alternative for Parkinson's disease patients," said Oded S. Lieberman, PhD, NeuroDerm's Chairman and CEO. "While constant levodopa plasma concentrations achieved through continuous levodopa infusion have been shown to bring significant benefit to Parkinson's patients, these options are generally impractical. In contrast, ND0611 may offer a new treatment alternative that can be widely adopted for chronic control of the most common problems affecting Parkinson's disease."

About NeuroDerm

NeuroDerm is an emerging pharmaceutical company that develops therapeutic dermal patches for the treatment of CNS diseases. NeuroDerm's technology is based on proprietary reformulations of well established oral drugs whose low bio-availability is the major impediment to better efficacy. The company's lead product is ND0611, a revolutionary skin patch for the treatment of Parkinson's disease. Other products for the treatment of various diseases, including ADD, ADHD, schizophrenia and Alzheimer's disease, are in different stages of development. NeuroDerm is headquartered in the Weizmann Science Park, Ness Ziona, Israel.

    Contact:

    Oded S. Lieberman
    PhD MBA, Chairman & CEO
    oded@neuroderm.com
    Tel.: +972-8-946-2729
    Cell: +1-617-517-6077



'/>"/>
SOURCE NeuroDerm Ltd
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. QRxPharma Successfully Completes Comparative Phase 1 Proof-of-Concept Study for MoxDuo(R) CR Tablet Formulation
2. MedAvante Opens Moscow Office and Successfully Completes First Centralized Ratings Assessment
3. Simcere Pharmaceutical Group Successfully Completes Endostar Phase IV Clinical Study
4. Sanofi-aventis Successfully Completes The Acquisition of Chattem, Inc.
5. Sanofi-aventis Successfully Completes Tender Offer for Chattem, Inc.
6. Phonak Successfully Hosts Hearing Care for Adults 2009 Conference
7. Tamaulipas Comparative Wound Healing Test Treatment Successfully Concluded
8. DBMS Consulting Successfully Completes Roll out of Oracle Health Sciences Applications (OHSA) Suite for SIRO Clinpharm
9. Guided Delivery Systems, Inc. Successfully Treats First Patient with Mitral Regurgitation
10. Hoviones TwinCaps(R) Inhaler Delivers Successfully in Phase III Clinical Trials for Influenza
11. American University of Beirut Medical Team Successfully Performs First Artificial Heart Implant in Lebanon
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... , April 19, 2017  IRIDEX Corporation (Nasdaq: ... financial results for the first quarter 2017 after the ... Company,s management team will host a corresponding conference call ... Investors interested in listening to the conference ... domestic callers or (703) 326-3030 for international callers, using ...
(Date:4/19/2017)... April 19, 2017 Global Prostate Cancer ... on the prostate cancer therapeutics market analyzes the ... Increasing prevalence of prostate cancer, launch of promising ... development of new drugs & therapeutic biological products, ... due to lesser side effects are some of ...
(Date:4/19/2017)... -- The Global Effective Microorganisms (EM) Market by ... covered and analysed the potential of Global Effective Microorganisms (EM) ... and growth factors. The report identifies and analyses the emerging ... global market. ... Tables and Figures, 6 Major Company Profiles, spread across 124 ...
Breaking Medicine Technology:
(Date:4/29/2017)... Orion, Michigan (PRWEB) , ... April 29, 2017 ... ... signs of fertility and infertility. These methods observe the naturally occurring signs ... in intercourse during the most fertile time. , Natural family planning and ...
(Date:4/29/2017)... ... ... More than half of Americans suffering from noise-induced hearing loss do not ... causes hearing loss? May 1 marks the beginning of Better Hearing & Speech Month—a ... as schedule a hearing evaluation for anyone with concerns about his/her hearing. , Approximately ...
(Date:4/28/2017)... ... April 28, 2017 , ... Accreditation Commission ... Home Care Association of America (HCAOA). This agreement allows HCAOA members to receive ... well as discounts on Accreditation University (AU) educational resources that help prepare HCAOA ...
(Date:4/28/2017)... ... April 28, 2017 , ... Horizon Blue Cross Blue Shield ... credit rating of “A” and its outlook as “stable.” At the same time, the ... have fallen in recent years, dip below “capital adequacy” thresholds required for its strong ...
(Date:4/28/2017)... ... April 28, 2017 , ... Ushio America ... lamps offer an instant energy-saving solution for F32T8 fluorescent lamps on most instant-start ... ballasts. These 50,000 hour rated lamps utilize the existing electronic ballast, saving labor ...
Breaking Medicine News(10 mins):